GSK plc vs Viatris Inc.: A Gross Profit Performance Breakdown

A Tale of Two Giants: GSK plc and Viatris Inc.

In the ever-evolving pharmaceutical industry, GSK plc and Viatris Inc. have emerged as key players, showcasing distinct trajectories in their gross profit performance over the past decade. From 2014 to 2023, GSK plc consistently demonstrated robust growth, with its gross profit peaking in 2021 at approximately 22.5 billion, marking a 44% increase from 2014. Meanwhile, Viatris Inc. experienced a remarkable surge, particularly from 2020 onwards, with its gross profit climbing by 76% to reach around 6.5 billion in 2022. This growth trajectory highlights Viatris Inc.'s strategic maneuvers in the market, despite starting from a lower base compared to GSK plc. As these companies continue to innovate and expand, their financial performances offer valuable insights into the competitive dynamics of the pharmaceutical sector.